Winslow Capital Management LLC lessened its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 16.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,225,331 shares of the medical research company’s stock after selling 429,153 shares during the quarter. Edwards Lifesciences Corporation comprises 1.4% of Winslow Capital Management LLC’s portfolio, making the stock its 28th biggest holding. Winslow Capital Management LLC owned 1.05% of Edwards Lifesciences Corporation worth $263,123,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. South Texas Money Management Ltd. raised its stake in Edwards Lifesciences Corporation by 157.9% during the 1st quarter. South Texas Money Management Ltd. now owns 344,816 shares of the medical research company’s stock valued at $32,437,000 after purchasing an additional 211,119 shares during the period. Financial Counselors Inc. raised its stake in Edwards Lifesciences Corporation by 2.1% during the 1st quarter. Financial Counselors Inc. now owns 13,637 shares of the medical research company’s stock valued at $1,283,000 after purchasing an additional 282 shares during the period. Westpac Banking Corp raised its stake in Edwards Lifesciences Corporation by 13.5% during the 2nd quarter. Westpac Banking Corp now owns 14,214 shares of the medical research company’s stock valued at $1,681,000 after purchasing an additional 1,691 shares during the period. Principal Financial Group Inc. raised its stake in Edwards Lifesciences Corporation by 41.9% during the 2nd quarter. Principal Financial Group Inc. now owns 465,885 shares of the medical research company’s stock valued at $55,086,000 after purchasing an additional 137,643 shares during the period. Finally, Vanguard Group Inc. raised its stake in Edwards Lifesciences Corporation by 2.5% during the 1st quarter. Vanguard Group Inc. now owns 20,341,668 shares of the medical research company’s stock valued at $1,913,541,000 after purchasing an additional 505,725 shares during the period. 82.08% of the stock is currently owned by institutional investors.

Several analysts recently issued reports on EW shares. SunTrust Banks, Inc. lifted their target price on Edwards Lifesciences Corporation to $14.00 and gave the company a “buy” rating in a research note on Monday, July 17th. Jefferies Group LLC reissued a “buy” rating and set a $115.00 target price on shares of Edwards Lifesciences Corporation in a research note on Friday, June 30th. Canaccord Genuity reissued a “buy” rating and set a $150.00 target price on shares of Edwards Lifesciences Corporation in a research note on Wednesday, June 28th. Royal Bank Of Canada reissued a “buy” rating on shares of Edwards Lifesciences Corporation in a research note on Tuesday, May 30th. Finally, Bank of America Corporation lifted their target price on Edwards Lifesciences Corporation from $120.00 to $140.00 and gave the company a “buy” rating in a research note on Tuesday, May 30th. Six investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $120.75.

Edwards Lifesciences Corporation (NYSE EW) traded down 0.67% during trading on Monday, reaching $109.90. The company had a trading volume of 216,826 shares. The firm has a market capitalization of $23.21 billion, a price-to-earnings ratio of 33.33 and a beta of 0.64. The company’s 50-day moving average is $113.80 and its 200 day moving average is $109.37. Edwards Lifesciences Corporation has a 52 week low of $81.12 and a 52 week high of $121.75.

Edwards Lifesciences Corporation (NYSE:EW) last issued its quarterly earnings data on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.20. The company had revenue of $842.00 million during the quarter, compared to analyst estimates of $839.16 million. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The firm’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same period in the prior year, the business posted $0.76 earnings per share. Equities analysts anticipate that Edwards Lifesciences Corporation will post $3.78 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This story was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another domain, it was stolen and republished in violation of US and international trademark and copyright law. The original version of this story can be accessed at https://www.dailypolitical.com/2017/09/25/edwards-lifesciences-corporation-ew-position-cut-by-winslow-capital-management-llc.html.

In related news, CEO Michael A. Mussallem sold 32,900 shares of the stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $114.80, for a total value of $3,776,920.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Catherine M. Szyman sold 4,681 shares of the stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $115.78, for a total value of $541,966.18. The disclosure for this sale can be found here. Insiders sold 182,501 shares of company stock valued at $20,847,236 over the last quarter. 2.13% of the stock is currently owned by company insiders.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.